surpass tirzepatide Effects of on adjudicated cardiovascular events in surpass tirzepatide surpass 4 tirzepatide

Understanding your genetic profile helps your provider select the right medication and dosing strategy from the start

Cognitive decline and dementia in diabetes mellitus: Mechanisms and clinical implications

Experts classify semaglutide as a GLP-1 receptor agonist

Community protocols hold each step at least 4 weeks and step back if GI side effects are intense

14.4 Cardiovascular Outcomes Trial of RYBELSUS in Adult Patients with Type 2 Diabetes Mellitus and High Risk of Having a Cardiovascular Event Trial 7 [Semaglutide Cardiovascular Outcomes Trial (SOUL), NCT03914326] was a randomized, double-blind, parallel-group, placebo-controlled trial

The baseline characteristics and demographics of patients pooled by study are summarised in Table S1 (in the supplementary material)